RCM
ALPN

RA Capital Management’s Alpine Immune Sciences Inc ALPN Stock Holding History

RA Capital Management’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,909,763
Closed -$93.6M – 79
2023
Q4 		$93.6M Buy
4,909,763
+218,585
+5% +$3.04M 1.46% 19
2023
Q3 		$53.7M Hold
4,691,178
– – 1.06% 27
2023
Q2 		$48.2M Buy
4,691,178
+3,063
+0.1% +$27.6K 0.91% 31
2023
Q1 		$36.2M Buy
4,688,115
+290,747
+7% +$2.32M 0.82% 37
2022
Q4 		$32.3M Buy
4,397,368
+40,736
+0.9% +$260K 0.66% 38
2022
Q3 		$31.4M Buy
+4,356,632
New +$35.9M 0.67% 45
2016
Q2 		– Sell
-153,216
Closed -$2.56M – 38
2016
Q1 		$2.56M Hold
153,216
– – 0.33% 38
2015
Q4 		$4.74M Hold
153,216
– – 0.47% 32
2015
Q3 		$7.95M Sell
153,216
-36,100
-19% -$2.37M 1.14% 29
2015
Q2 		$11.5M Buy
+189,316
New +$11.3M 1.15% 28

Other funds holding ALPN

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

RA Capital Management's ALPN Position: Q1 2024 in Review

RA Capital Management sold out of Alpine Immune Sciences Inc (ALPN) in Q1 2024, closing a stake of 4,909,763 shares — an estimated $93.6M sold.

RA Capital Management first reported a position in ALPN in Q2 2015 and held it in 10 quarters. The position peaked at $93.6M in Q4 2023. 180 funds tracked by Wall St. Rank hold ALPN as of Q1 2024.

  • RA Capital Management reported no remaining Alpine Immune Sciences Inc position as of Q1 2024 after selling out during the quarter.
  • RA Capital Management sold 4,909,763 Alpine Immune Sciences Inc shares in Q1 2024, an estimated $93.6M.
  • RA Capital Management first reported a position in Alpine Immune Sciences Inc in Q2 2015 and held it in 10 quarters.
  • RA Capital Management's Alpine Immune Sciences Inc position peaked at $93.6M in Q4 2023.
  • 180 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q1 2024.

Based on RA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.